TANDEM Therapeutics is a discovery stage Swiss biopharmaceutical company bringing a novel precision targeting approaches to fibrosis and fibrotic cancers. We advance over 15 years of transformative research and development at ETH Zürich and Paul Scherrer Institut in the field of extracellular matrix biology and the critical role it plays in the pathology of fibrotic cancers & organ fibrosis. The therapeutic platform is based on Matrix Targeting Peptides (MTP) that conditionally target disease associated matrix alterations that are known to be directly associated with several fibrotic diseases.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Wagistrasse 18, Schlieren,8952,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://tandem-tx.com/
- HQ
- Schlieren
Tandem Therapeutics Questions
Tandem Therapeutics's website is https://tandem-tx.com/
Tandem Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/tandem-therapeutics
Tandem Therapeutics has
5 employees.
View email and phone details for 5
employees at Tandem Therapeutics.
Tandem Therapeutics's industry is
Biotechnology Research
Tandem Therapeutics's top competitors are
Prevision Medicine,
Apersys Ag,
Procavea Biotech,
Cellx Biosolutions,
Myria Biosciences Ag,
Zuriq,
Evis Bioscience Ag,
Winduction Ag,
Unbound Potential,
Solskin By Zurich Soft Robotics.
Tandem Therapeutics's categories are Biotechnology Research
Tandem Therapeutics's founding year is 2023
